UNRESECTABLE MELANOMA

This study is testing whether doctors can safely stop a standard immunotherapy treatment early for patients with advanced melanoma. It uses PET scans and biopsies taken after one year of treatment to decide who can stop their medication. The goal is to see if patients can avoid u…

This study is testing whether adding a personalized cancer vaccine called EVX-01 to standard immunotherapy (pembrolizumab) can better control advanced melanoma. It involves 17 adults whose melanoma has spread or cannot be removed by surgery and who have not yet received this type…

This early-stage study aimed to test the safety and initial effectiveness of a personalized cell therapy called STIL101 for patients with advanced cancers that have spread or cannot be removed by surgery. The therapy involved growing a patient's own immune cells from a tumor samp…

This study is testing whether adding a third drug, navitoclax, to two existing melanoma drugs (dabrafenib and trametinib) can help shrink tumors more effectively. It involves adults with advanced, BRAF-mutant melanoma or other solid tumors that have spread or cannot be removed by…

This early-stage study is testing the safety and best dose of a new drug combination for advanced melanoma that has spread or cannot be surgically removed. It combines pembrolizumab, an immunotherapy drug, with ibrutinib, a drug that may block cancer cell growth. The goal is to s…

This study tested whether adding a drug called GM-CSF (sargramostim) to an existing immune-boosting cancer drug (ipilimumab) could help patients with advanced melanoma live longer. The trial involved 245 adults whose melanoma could not be removed by surgery. Researchers compared …

This early-stage trial is testing the safety of a new combination treatment for people with advanced cancers that have spread and cannot be removed by surgery. Doctors inject immune-stimulating drugs directly into a tumor, then give a small dose of radiation to that same spot. Th…

This study is for people with advanced melanoma that has a specific BRAF gene mutation and cannot be removed by surgery. It is testing which order of two powerful treatment combinations leads to longer survival. One group starts with immunotherapy (ipilimumab + nivolumab) and swi…

This study is testing two different combinations of three drugs to see if they are safe and effective for people with advanced melanoma that has a specific genetic change (BRAF mutation) and has spread or cannot be removed by surgery. The goal is to control the cancer by using an…

This early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…

This early-phase study is testing a combination of immunotherapy drugs (nivolumab and ipilimumab) along with standard transplant medications (tacrolimus and prednisone) in kidney transplant patients with advanced skin cancers that have spread or cannot be removed by surgery. The …

This study is testing whether taking planned breaks from two targeted cancer drugs (dabrafenib and trametinib) is as effective as taking them continuously for people with advanced melanoma that has a specific genetic change (BRAF mutation). It aims to see if the 'on-and-off' sche…

This study is testing whether eating a high-fiber diet can improve gut health and help the immune system fight cancer in patients with advanced melanoma who are receiving standard immunotherapy. Fifty participants will be randomly assigned to follow either a high-fiber diet or a …

This early-stage study is testing a personalized treatment called TBio-4101 for people with advanced melanoma that hasn't responded to standard therapies. Doctors take immune cells from a patient's tumor, grow them in large numbers in a lab, and then infuse them back into the pat…

This study is testing whether a two-part immunotherapy can help patients with advanced melanoma whose cancer has continued to grow despite standard immune-based treatments. It combines a modified virus injected directly into tumors (T-VEC) with an intravenous drug (pembrolizumab)…

This study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…